BioCentury | Aug 6, 2020
Emerging Company Profile

Off-the-shelf cell therapy pioneers, Versant launch Matterhorn to tackle broad range of cancers

...first company to develop therapeutic MR1T cells. A Nature Immunology paper published in January by Cardiff...
...Major histocompatibility complex, class I-related TCR - T cell receptor Danielle Golovin, Staff Writer Versant Ventures Ervaxx Ltd. Cardiff...
BioCentury | Apr 1, 2020
Emerging Company Profile

Aspen plans to drive iPS cell therapy into Parkinson’s patients with $70M A round

...Disease focus: Neurology Clinical status: Preclinical Founded: 2018 by Jeanne Loring, Andrés Bratt-Leal University collaborators: Cardiff...
BioCentury | Jan 25, 2020
Preclinical News

Ervaxx pursues non-peptide tumor antigens via Cardiff University TCR, T cell deal

...A research collaboration with Cardiff University will enable Ervaxx to go beyond targeting neoantigens derived from...
...TCRs against cancer-specific antigens, and may develop and commercialize any resulting immunotherapies and cancer vaccines. Cardiff...
...MR1 (HLALS) - Major histocompatibility complex, class I-related; TCR - T cell receptor Sandi Wong, Assistant Editor Cardiff...
BioCentury | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

...identify chronic lymphocytic leukemia (CLL) patients at risk of progression, according to an abstract from Cardiff...
...Inc. Memorial Sloan Kettering Cancer Center ImCheck Therapeutics S.A.S. Shanghai Junshi Biosciences Co. Ltd. Broad Institute of MIT and Harvard Cardiff...
BioCentury | Nov 5, 2019
Company News

Ervaxx debuts with a new source of neoantigens

...Clinical status: Preclinical Founded: 2017 by Houman Ashrafian, George Kassiotis and Drew Pardoll University collaborators: Cardiff...
BioCentury | Oct 18, 2019
Company News

Management tracks: Sirtex makes interim CEO permanent; plus Magenta, Pyxis, Stoke, Cadent, StemoniX, Enzyvant, Syapse and Stalicla

...chief of science, succeeding Luigi Boccuto. Baudouin was a senior lecturer and team leader at Cardiff...
BioCentury | Aug 14, 2019
Company News

Aug. 14 Company Quick Takes: Myriad plunges on sales concerns; plus AbbVie-Allergan, TB Alliance, Akari, Carmine

...of Cardiff for delivery systems research ReNeuron Group plc (AIM:RENE) is partnering with University of Cardiff...
BioCentury | Jun 19, 2019
Company News

June 18 Company Quick Takes: Sino-Akeso JV, plus Oxford Drug Design, Be The Match and more

...integrate cell, gene therapy supply chain platforms Be The Match BioTherapies partnered with TrakCel Ltd. (Cardiff...
BioCentury | May 3, 2019
Emerging Company Profile

Vineti: Keeping cell therapies on track

...Jacksonville, Fla. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Tessa Therapeutics Pte. Ltd., Singapore TrakCel Ltd., Cardiff...
BioCentury | Apr 12, 2018
Translation in Brief

Shape recognition

...A Cardiff University team has engineered a D-peptide that mimicked the T cell agonist activity of...
...respond to non-natural ligands with chemistries similar to the natural peptides. Sewell is professor at Cardiff...
...and Immunity. “Non-biological shapes can induce T cells to then see biological shapes.” Andrew Sewell, Cardiff...
Items per page:
1 - 10 of 137
BioCentury | Aug 6, 2020
Emerging Company Profile

Off-the-shelf cell therapy pioneers, Versant launch Matterhorn to tackle broad range of cancers

...first company to develop therapeutic MR1T cells. A Nature Immunology paper published in January by Cardiff...
...Major histocompatibility complex, class I-related TCR - T cell receptor Danielle Golovin, Staff Writer Versant Ventures Ervaxx Ltd. Cardiff...
BioCentury | Apr 1, 2020
Emerging Company Profile

Aspen plans to drive iPS cell therapy into Parkinson’s patients with $70M A round

...Disease focus: Neurology Clinical status: Preclinical Founded: 2018 by Jeanne Loring, Andrés Bratt-Leal University collaborators: Cardiff...
BioCentury | Jan 25, 2020
Preclinical News

Ervaxx pursues non-peptide tumor antigens via Cardiff University TCR, T cell deal

...A research collaboration with Cardiff University will enable Ervaxx to go beyond targeting neoantigens derived from...
...TCRs against cancer-specific antigens, and may develop and commercialize any resulting immunotherapies and cancer vaccines. Cardiff...
...MR1 (HLALS) - Major histocompatibility complex, class I-related; TCR - T cell receptor Sandi Wong, Assistant Editor Cardiff...
BioCentury | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

...identify chronic lymphocytic leukemia (CLL) patients at risk of progression, according to an abstract from Cardiff...
...Inc. Memorial Sloan Kettering Cancer Center ImCheck Therapeutics S.A.S. Shanghai Junshi Biosciences Co. Ltd. Broad Institute of MIT and Harvard Cardiff...
BioCentury | Nov 5, 2019
Company News

Ervaxx debuts with a new source of neoantigens

...Clinical status: Preclinical Founded: 2017 by Houman Ashrafian, George Kassiotis and Drew Pardoll University collaborators: Cardiff...
BioCentury | Oct 18, 2019
Company News

Management tracks: Sirtex makes interim CEO permanent; plus Magenta, Pyxis, Stoke, Cadent, StemoniX, Enzyvant, Syapse and Stalicla

...chief of science, succeeding Luigi Boccuto. Baudouin was a senior lecturer and team leader at Cardiff...
BioCentury | Aug 14, 2019
Company News

Aug. 14 Company Quick Takes: Myriad plunges on sales concerns; plus AbbVie-Allergan, TB Alliance, Akari, Carmine

...of Cardiff for delivery systems research ReNeuron Group plc (AIM:RENE) is partnering with University of Cardiff...
BioCentury | Jun 19, 2019
Company News

June 18 Company Quick Takes: Sino-Akeso JV, plus Oxford Drug Design, Be The Match and more

...integrate cell, gene therapy supply chain platforms Be The Match BioTherapies partnered with TrakCel Ltd. (Cardiff...
BioCentury | May 3, 2019
Emerging Company Profile

Vineti: Keeping cell therapies on track

...Jacksonville, Fla. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Tessa Therapeutics Pte. Ltd., Singapore TrakCel Ltd., Cardiff...
BioCentury | Apr 12, 2018
Translation in Brief

Shape recognition

...A Cardiff University team has engineered a D-peptide that mimicked the T cell agonist activity of...
...respond to non-natural ligands with chemistries similar to the natural peptides. Sewell is professor at Cardiff...
...and Immunity. “Non-biological shapes can induce T cells to then see biological shapes.” Andrew Sewell, Cardiff...
Items per page:
1 - 10 of 137